Five of these 18 exhibited overrepresented tumor-specific staining in urothelial bladder cancer samples (Additional file 4: Fig. S4L, M), including PKN1, which had approved drug and were also associated with prognosis (Additional file 4: Fig. S4N). Here, PKN1 is linked to bladder transitional cell carcinoma.